ArticleJAMA network open2022

Use of US Food and Drug Administration Expedited Drug Development and Review Programs by Orphan and Nonorphan Novel Drugs Approved From 2008 to 2021.

Andrea N Monge et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.